Global Circulating Tumour DNA (ctDNA) Testing Market Research Report 2025(Status and Outlook)
Report Overview
Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. Most DNA is inside a cell?s nucleus. As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down and their contents, including DNA, are released into the bloodstream. ctDNA are small pieces of DNA, usually comprising fewer than 200 building blocks (nucleotides) in length.The quantity of ctDNA varies among individuals and depends on the type of tumor, its location, and for cancerous tumors, the cancer stage.Circulating-tumor DNA (ctDNA) refers to fragments of DNA derived from tumor cells and circulating in the blood together with cell-free DNA from other sources. Circulating tumor DNA (ctDNA) analyses are minimally invasive and accessible for risk stratification or treatment response monitoring of cancer patients. Compared to tumor biopsy analysis, they are not only less invasive, but also provide a more representative picture, allowing capturing both tumor heterogeneity and multiple tumor sites.
This report provides a deep insight into the global Circulating Tumour DNA (ctDNA) Testing market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Circulating Tumour DNA (ctDNA) Testing Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Circulating Tumour DNA (ctDNA) Testing market in any manner.
Global Circulating Tumour DNA (ctDNA) Testing Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Nexomics
Roche
ORIOMICS
Signatera
Illumina
Sysmex Corporation
Bio-Rad
Biocartis
QIAGEN
GuardantHealth
GSK plc
AstraZeneca
NeoGenomics Laboratories
AmoyDx
Annoroad
Burning Rock Biotech
Market Segmentation (by Type)
Gastric Cancer Methylation Screening
Esophageal Cancer Methylation Screening
Colorectal Cancer Methylation Screening
Lung Cancer Methylation Screening
Liver Cancer Methylation Screening
Other Cancer Screening
Market Segmentation (by Application)
Hospital
Medical Center
Laboratory
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Circulating Tumour DNA (ctDNA) Testing Market
Overview of the regional outlook of the Circulating Tumour DNA (ctDNA) Testing Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Circulating Tumour DNA (ctDNA) Testing Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Circulating Tumour DNA (ctDNA) Testing, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. Most DNA is inside a cell?s nucleus. As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down and their contents, including DNA, are released into the bloodstream. ctDNA are small pieces of DNA, usually comprising fewer than 200 building blocks (nucleotides) in length.The quantity of ctDNA varies among individuals and depends on the type of tumor, its location, and for cancerous tumors, the cancer stage.Circulating-tumor DNA (ctDNA) refers to fragments of DNA derived from tumor cells and circulating in the blood together with cell-free DNA from other sources. Circulating tumor DNA (ctDNA) analyses are minimally invasive and accessible for risk stratification or treatment response monitoring of cancer patients. Compared to tumor biopsy analysis, they are not only less invasive, but also provide a more representative picture, allowing capturing both tumor heterogeneity and multiple tumor sites.
This report provides a deep insight into the global Circulating Tumour DNA (ctDNA) Testing market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Circulating Tumour DNA (ctDNA) Testing Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Circulating Tumour DNA (ctDNA) Testing market in any manner.
Global Circulating Tumour DNA (ctDNA) Testing Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Nexomics
Roche
ORIOMICS
Signatera
Illumina
Sysmex Corporation
Bio-Rad
Biocartis
QIAGEN
GuardantHealth
GSK plc
AstraZeneca
NeoGenomics Laboratories
AmoyDx
Annoroad
Burning Rock Biotech
Market Segmentation (by Type)
Gastric Cancer Methylation Screening
Esophageal Cancer Methylation Screening
Colorectal Cancer Methylation Screening
Lung Cancer Methylation Screening
Liver Cancer Methylation Screening
Other Cancer Screening
Market Segmentation (by Application)
Hospital
Medical Center
Laboratory
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Circulating Tumour DNA (ctDNA) Testing Market
Overview of the regional outlook of the Circulating Tumour DNA (ctDNA) Testing Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Circulating Tumour DNA (ctDNA) Testing Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Circulating Tumour DNA (ctDNA) Testing, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Circulating Tumour DNA (ctDNA) Testing
1.2 Key Market Segments
1.2.1 Circulating Tumour DNA (ctDNA) Testing Segment by Type
1.2.2 Circulating Tumour DNA (ctDNA) Testing Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Circulating Tumour DNA (ctDNA) Testing Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Circulating Tumour DNA (ctDNA) Testing Product Life Cycle
3.3 Global Circulating Tumour DNA (ctDNA) Testing Sales by Manufacturers (2020-2025)
3.4 Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Manufacturers (2020-2025)
3.5 Circulating Tumour DNA (ctDNA) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Circulating Tumour DNA (ctDNA) Testing Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Circulating Tumour DNA (ctDNA) Testing Market Competitive Situation and Trends
3.8.1 Circulating Tumour DNA (ctDNA) Testing Market Concentration Rate
3.8.2 Global 5 and 10 Largest Circulating Tumour DNA (ctDNA) Testing Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 CIRCULATING TUMOUR DNA (CTDNA) TESTING INDUSTRY CHAIN ANALYSIS
4.1 Circulating Tumour DNA (ctDNA) Testing Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Circulating Tumour DNA (ctDNA) Testing Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Circulating Tumour DNA (ctDNA) Testing Market
5.7 ESG Ratings of Leading Companies
6 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Type (2020-2025)
6.3 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2020-2025)
6.4 Global Circulating Tumour DNA (ctDNA) Testing Price by Type (2020-2025)
7 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Circulating Tumour DNA (ctDNA) Testing Market Sales by Application (2020-2025)
7.3 Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) by Application (2020-2025)
7.4 Global Circulating Tumour DNA (ctDNA) Testing Sales Growth Rate by Application (2020-2025)
8 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET SALES BY REGION
8.1 Global Circulating Tumour DNA (ctDNA) Testing Sales by Region
8.1.1 Global Circulating Tumour DNA (ctDNA) Testing Sales by Region
8.1.2 Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region
8.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region
8.2.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region
8.2.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region
8.3 North America
8.3.1 North America Circulating Tumour DNA (ctDNA) Testing Sales by Country
8.3.2 North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Circulating Tumour DNA (ctDNA) Testing Sales by Country
8.4.2 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales by Region
8.5.2 Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Circulating Tumour DNA (ctDNA) Testing Sales by Country
8.6.2 South America Circulating Tumour DNA (ctDNA) Testing Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales by Region
8.7.2 Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET PRODUCTION BY REGION
9.1 Global Production of Circulating Tumour DNA (ctDNA) Testing by Region(2020-2025)
9.2 Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Region (2020-2025)
9.3 Global Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Circulating Tumour DNA (ctDNA) Testing Production
9.4.1 North America Circulating Tumour DNA (ctDNA) Testing Production Growth Rate (2020-2025)
9.4.2 North America Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Circulating Tumour DNA (ctDNA) Testing Production
9.5.1 Europe Circulating Tumour DNA (ctDNA) Testing Production Growth Rate (2020-2025)
9.5.2 Europe Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Circulating Tumour DNA (ctDNA) Testing Production (2020-2025)
9.6.1 Japan Circulating Tumour DNA (ctDNA) Testing Production Growth Rate (2020-2025)
9.6.2 Japan Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Circulating Tumour DNA (ctDNA) Testing Production (2020-2025)
9.7.1 China Circulating Tumour DNA (ctDNA) Testing Production Growth Rate (2020-2025)
9.7.2 China Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Nexomics
10.1.1 Nexomics Basic Information
10.1.2 Nexomics Circulating Tumour DNA (ctDNA) Testing Product Overview
10.1.3 Nexomics Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.1.4 Nexomics Business Overview
10.1.5 Nexomics SWOT Analysis
10.1.6 Nexomics Recent Developments
10.2 Roche
10.2.1 Roche Basic Information
10.2.2 Roche Circulating Tumour DNA (ctDNA) Testing Product Overview
10.2.3 Roche Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.2.4 Roche Business Overview
10.2.5 Roche SWOT Analysis
10.2.6 Roche Recent Developments
10.3 ORIOMICS
10.3.1 ORIOMICS Basic Information
10.3.2 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Overview
10.3.3 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.3.4 ORIOMICS Business Overview
10.3.5 ORIOMICS SWOT Analysis
10.3.6 ORIOMICS Recent Developments
10.4 Signatera
10.4.1 Signatera Basic Information
10.4.2 Signatera Circulating Tumour DNA (ctDNA) Testing Product Overview
10.4.3 Signatera Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.4.4 Signatera Business Overview
10.4.5 Signatera Recent Developments
10.5 Illumina
10.5.1 Illumina Basic Information
10.5.2 Illumina Circulating Tumour DNA (ctDNA) Testing Product Overview
10.5.3 Illumina Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.5.4 Illumina Business Overview
10.5.5 Illumina Recent Developments
10.6 Sysmex Corporation
10.6.1 Sysmex Corporation Basic Information
10.6.2 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Overview
10.6.3 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.6.4 Sysmex Corporation Business Overview
10.6.5 Sysmex Corporation Recent Developments
10.7 Bio-Rad
10.7.1 Bio-Rad Basic Information
10.7.2 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Overview
10.7.3 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.7.4 Bio-Rad Business Overview
10.7.5 Bio-Rad Recent Developments
10.8 Biocartis
10.8.1 Biocartis Basic Information
10.8.2 Biocartis Circulating Tumour DNA (ctDNA) Testing Product Overview
10.8.3 Biocartis Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.8.4 Biocartis Business Overview
10.8.5 Biocartis Recent Developments
10.9 QIAGEN
10.9.1 QIAGEN Basic Information
10.9.2 QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Overview
10.9.3 QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.9.4 QIAGEN Business Overview
10.9.5 QIAGEN Recent Developments
10.10 GuardantHealth
10.10.1 GuardantHealth Basic Information
10.10.2 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Overview
10.10.3 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.10.4 GuardantHealth Business Overview
10.10.5 GuardantHealth Recent Developments
10.11 GSK plc
10.11.1 GSK plc Basic Information
10.11.2 GSK plc Circulating Tumour DNA (ctDNA) Testing Product Overview
10.11.3 GSK plc Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.11.4 GSK plc Business Overview
10.11.5 GSK plc Recent Developments
10.12 AstraZeneca
10.12.1 AstraZeneca Basic Information
10.12.2 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Overview
10.12.3 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.12.4 AstraZeneca Business Overview
10.12.5 AstraZeneca Recent Developments
10.13 NeoGenomics Laboratories
10.13.1 NeoGenomics Laboratories Basic Information
10.13.2 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Overview
10.13.3 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.13.4 NeoGenomics Laboratories Business Overview
10.13.5 NeoGenomics Laboratories Recent Developments
10.14 AmoyDx
10.14.1 AmoyDx Basic Information
10.14.2 AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Overview
10.14.3 AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.14.4 AmoyDx Business Overview
10.14.5 AmoyDx Recent Developments
10.15 Annoroad
10.15.1 Annoroad Basic Information
10.15.2 Annoroad Circulating Tumour DNA (ctDNA) Testing Product Overview
10.15.3 Annoroad Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.15.4 Annoroad Business Overview
10.15.5 Annoroad Recent Developments
10.16 Burning Rock Biotech
10.16.1 Burning Rock Biotech Basic Information
10.16.2 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Overview
10.16.3 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.16.4 Burning Rock Biotech Business Overview
10.16.5 Burning Rock Biotech Recent Developments
11 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET FORECAST BY REGION
11.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast
11.2 Global Circulating Tumour DNA (ctDNA) Testing Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country
11.2.3 Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Region
11.2.4 South America Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Circulating Tumour DNA (ctDNA) Testing by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Circulating Tumour DNA (ctDNA) Testing Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Circulating Tumour DNA (ctDNA) Testing by Type (2026-2033)
12.1.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Circulating Tumour DNA (ctDNA) Testing by Type (2026-2033)
12.2 Global Circulating Tumour DNA (ctDNA) Testing Market Forecast by Application (2026-2033)
12.2.1 Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) Forecast by Application
12.2.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Circulating Tumour DNA (ctDNA) Testing
1.2 Key Market Segments
1.2.1 Circulating Tumour DNA (ctDNA) Testing Segment by Type
1.2.2 Circulating Tumour DNA (ctDNA) Testing Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Circulating Tumour DNA (ctDNA) Testing Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Circulating Tumour DNA (ctDNA) Testing Product Life Cycle
3.3 Global Circulating Tumour DNA (ctDNA) Testing Sales by Manufacturers (2020-2025)
3.4 Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Manufacturers (2020-2025)
3.5 Circulating Tumour DNA (ctDNA) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Circulating Tumour DNA (ctDNA) Testing Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Circulating Tumour DNA (ctDNA) Testing Market Competitive Situation and Trends
3.8.1 Circulating Tumour DNA (ctDNA) Testing Market Concentration Rate
3.8.2 Global 5 and 10 Largest Circulating Tumour DNA (ctDNA) Testing Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 CIRCULATING TUMOUR DNA (CTDNA) TESTING INDUSTRY CHAIN ANALYSIS
4.1 Circulating Tumour DNA (ctDNA) Testing Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Circulating Tumour DNA (ctDNA) Testing Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Circulating Tumour DNA (ctDNA) Testing Market
5.7 ESG Ratings of Leading Companies
6 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Type (2020-2025)
6.3 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2020-2025)
6.4 Global Circulating Tumour DNA (ctDNA) Testing Price by Type (2020-2025)
7 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Circulating Tumour DNA (ctDNA) Testing Market Sales by Application (2020-2025)
7.3 Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) by Application (2020-2025)
7.4 Global Circulating Tumour DNA (ctDNA) Testing Sales Growth Rate by Application (2020-2025)
8 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET SALES BY REGION
8.1 Global Circulating Tumour DNA (ctDNA) Testing Sales by Region
8.1.1 Global Circulating Tumour DNA (ctDNA) Testing Sales by Region
8.1.2 Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region
8.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region
8.2.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region
8.2.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region
8.3 North America
8.3.1 North America Circulating Tumour DNA (ctDNA) Testing Sales by Country
8.3.2 North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Circulating Tumour DNA (ctDNA) Testing Sales by Country
8.4.2 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales by Region
8.5.2 Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Circulating Tumour DNA (ctDNA) Testing Sales by Country
8.6.2 South America Circulating Tumour DNA (ctDNA) Testing Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales by Region
8.7.2 Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET PRODUCTION BY REGION
9.1 Global Production of Circulating Tumour DNA (ctDNA) Testing by Region(2020-2025)
9.2 Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Region (2020-2025)
9.3 Global Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Circulating Tumour DNA (ctDNA) Testing Production
9.4.1 North America Circulating Tumour DNA (ctDNA) Testing Production Growth Rate (2020-2025)
9.4.2 North America Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Circulating Tumour DNA (ctDNA) Testing Production
9.5.1 Europe Circulating Tumour DNA (ctDNA) Testing Production Growth Rate (2020-2025)
9.5.2 Europe Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Circulating Tumour DNA (ctDNA) Testing Production (2020-2025)
9.6.1 Japan Circulating Tumour DNA (ctDNA) Testing Production Growth Rate (2020-2025)
9.6.2 Japan Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Circulating Tumour DNA (ctDNA) Testing Production (2020-2025)
9.7.1 China Circulating Tumour DNA (ctDNA) Testing Production Growth Rate (2020-2025)
9.7.2 China Circulating Tumour DNA (ctDNA) Testing Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Nexomics
10.1.1 Nexomics Basic Information
10.1.2 Nexomics Circulating Tumour DNA (ctDNA) Testing Product Overview
10.1.3 Nexomics Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.1.4 Nexomics Business Overview
10.1.5 Nexomics SWOT Analysis
10.1.6 Nexomics Recent Developments
10.2 Roche
10.2.1 Roche Basic Information
10.2.2 Roche Circulating Tumour DNA (ctDNA) Testing Product Overview
10.2.3 Roche Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.2.4 Roche Business Overview
10.2.5 Roche SWOT Analysis
10.2.6 Roche Recent Developments
10.3 ORIOMICS
10.3.1 ORIOMICS Basic Information
10.3.2 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Overview
10.3.3 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.3.4 ORIOMICS Business Overview
10.3.5 ORIOMICS SWOT Analysis
10.3.6 ORIOMICS Recent Developments
10.4 Signatera
10.4.1 Signatera Basic Information
10.4.2 Signatera Circulating Tumour DNA (ctDNA) Testing Product Overview
10.4.3 Signatera Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.4.4 Signatera Business Overview
10.4.5 Signatera Recent Developments
10.5 Illumina
10.5.1 Illumina Basic Information
10.5.2 Illumina Circulating Tumour DNA (ctDNA) Testing Product Overview
10.5.3 Illumina Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.5.4 Illumina Business Overview
10.5.5 Illumina Recent Developments
10.6 Sysmex Corporation
10.6.1 Sysmex Corporation Basic Information
10.6.2 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Overview
10.6.3 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.6.4 Sysmex Corporation Business Overview
10.6.5 Sysmex Corporation Recent Developments
10.7 Bio-Rad
10.7.1 Bio-Rad Basic Information
10.7.2 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Overview
10.7.3 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.7.4 Bio-Rad Business Overview
10.7.5 Bio-Rad Recent Developments
10.8 Biocartis
10.8.1 Biocartis Basic Information
10.8.2 Biocartis Circulating Tumour DNA (ctDNA) Testing Product Overview
10.8.3 Biocartis Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.8.4 Biocartis Business Overview
10.8.5 Biocartis Recent Developments
10.9 QIAGEN
10.9.1 QIAGEN Basic Information
10.9.2 QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Overview
10.9.3 QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.9.4 QIAGEN Business Overview
10.9.5 QIAGEN Recent Developments
10.10 GuardantHealth
10.10.1 GuardantHealth Basic Information
10.10.2 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Overview
10.10.3 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.10.4 GuardantHealth Business Overview
10.10.5 GuardantHealth Recent Developments
10.11 GSK plc
10.11.1 GSK plc Basic Information
10.11.2 GSK plc Circulating Tumour DNA (ctDNA) Testing Product Overview
10.11.3 GSK plc Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.11.4 GSK plc Business Overview
10.11.5 GSK plc Recent Developments
10.12 AstraZeneca
10.12.1 AstraZeneca Basic Information
10.12.2 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Overview
10.12.3 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.12.4 AstraZeneca Business Overview
10.12.5 AstraZeneca Recent Developments
10.13 NeoGenomics Laboratories
10.13.1 NeoGenomics Laboratories Basic Information
10.13.2 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Overview
10.13.3 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.13.4 NeoGenomics Laboratories Business Overview
10.13.5 NeoGenomics Laboratories Recent Developments
10.14 AmoyDx
10.14.1 AmoyDx Basic Information
10.14.2 AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Overview
10.14.3 AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.14.4 AmoyDx Business Overview
10.14.5 AmoyDx Recent Developments
10.15 Annoroad
10.15.1 Annoroad Basic Information
10.15.2 Annoroad Circulating Tumour DNA (ctDNA) Testing Product Overview
10.15.3 Annoroad Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.15.4 Annoroad Business Overview
10.15.5 Annoroad Recent Developments
10.16 Burning Rock Biotech
10.16.1 Burning Rock Biotech Basic Information
10.16.2 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Overview
10.16.3 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Market Performance
10.16.4 Burning Rock Biotech Business Overview
10.16.5 Burning Rock Biotech Recent Developments
11 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET FORECAST BY REGION
11.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast
11.2 Global Circulating Tumour DNA (ctDNA) Testing Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country
11.2.3 Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Region
11.2.4 South America Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Circulating Tumour DNA (ctDNA) Testing by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Circulating Tumour DNA (ctDNA) Testing Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Circulating Tumour DNA (ctDNA) Testing by Type (2026-2033)
12.1.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Circulating Tumour DNA (ctDNA) Testing by Type (2026-2033)
12.2 Global Circulating Tumour DNA (ctDNA) Testing Market Forecast by Application (2026-2033)
12.2.1 Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) Forecast by Application
12.2.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Circulating Tumour DNA (ctDNA) Testing Market Size Comparison by Region (M USD)
Table 5. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Circulating Tumour DNA (ctDNA) Testing Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Circulating Tumour DNA (ctDNA) Testing Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumour DNA (ctDNA) Testing as of 2024)
Table 10. Global Market Circulating Tumour DNA (ctDNA) Testing Average Price (USD/MT) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Circulating Tumour DNA (ctDNA) Testing Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Circulating Tumour DNA (ctDNA) Testing Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Circulating Tumour DNA (ctDNA) Testing Sales by Type (K MT)
Table 26. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Type (M USD)
Table 27. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) by Type (2020-2025)
Table 28. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Type (2020-2025)
Table 29. Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) by Type (2020-2025)
Table 30. Global Circulating Tumour DNA (ctDNA) Testing Market Size Share by Type (2020-2025)
Table 31. Global Circulating Tumour DNA (ctDNA) Testing Price (USD/MT) by Type (2020-2025)
Table 32. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) by Application
Table 33. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Application
Table 34. Global Circulating Tumour DNA (ctDNA) Testing Sales by Application (2020-2025) & (K MT)
Table 35. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Application (2020-2025)
Table 36. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2020-2025) & (M USD)
Table 37. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Application (2020-2025)
Table 38. Global Circulating Tumour DNA (ctDNA) Testing Sales Growth Rate by Application (2020-2025)
Table 39. Global Circulating Tumour DNA (ctDNA) Testing Sales by Region (2020-2025) & (K MT)
Table 40. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region (2020-2025)
Table 41. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2020-2025) & (M USD)
Table 42. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2020-2025)
Table 43. North America Circulating Tumour DNA (ctDNA) Testing Sales by Country (2020-2025) & (K MT)
Table 44. North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Circulating Tumour DNA (ctDNA) Testing Sales by Country (2020-2025) & (K MT)
Table 46. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2020-2025) & (M USD)
Table 49. South America Circulating Tumour DNA (ctDNA) Testing Sales by Country (2020-2025) & (K MT)
Table 50. South America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2020-2025) & (M USD)
Table 53. Global Circulating Tumour DNA (ctDNA) Testing Production (K MT) by Region(2020-2025)
Table 54. Global Circulating Tumour DNA (ctDNA) Testing Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Region (2020-2025)
Table 56. Global Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 57. North America Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 58. Europe Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 59. Japan Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 60. China Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 61. Nexomics Basic Information
Table 62. Nexomics Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 63. Nexomics Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 64. Nexomics Business Overview
Table 65. Nexomics SWOT Analysis
Table 66. Nexomics Recent Developments
Table 67. Roche Basic Information
Table 68. Roche Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 69. Roche Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 70. Roche Business Overview
Table 71. Roche SWOT Analysis
Table 72. Roche Recent Developments
Table 73. ORIOMICS Basic Information
Table 74. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 75. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 76. ORIOMICS Business Overview
Table 77. ORIOMICS SWOT Analysis
Table 78. ORIOMICS Recent Developments
Table 79. Signatera Basic Information
Table 80. Signatera Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 81. Signatera Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 82. Signatera Business Overview
Table 83. Signatera Recent Developments
Table 84. Illumina Basic Information
Table 85. Illumina Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 86. Illumina Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 87. Illumina Business Overview
Table 88. Illumina Recent Developments
Table 89. Sysmex Corporation Basic Information
Table 90. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 91. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 92. Sysmex Corporation Business Overview
Table 93. Sysmex Corporation Recent Developments
Table 94. Bio-Rad Basic Information
Table 95. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 96. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 97. Bio-Rad Business Overview
Table 98. Bio-Rad Recent Developments
Table 99. Biocartis Basic Information
Table 100. Biocartis Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 101. Biocartis Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 102. Biocartis Business Overview
Table 103. Biocartis Recent Developments
Table 104. QIAGEN Basic Information
Table 105. QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 106. QIAGEN Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 107. QIAGEN Business Overview
Table 108. QIAGEN Recent Developments
Table 109. GuardantHealth Basic Information
Table 110. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 111. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 112. GuardantHealth Business Overview
Table 113. GuardantHealth Recent Developments
Table 114. GSK plc Basic Information
Table 115. GSK plc Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 116. GSK plc Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 117. GSK plc Business Overview
Table 118. GSK plc Recent Developments
Table 119. AstraZeneca Basic Information
Table 120. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 121. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 122. AstraZeneca Business Overview
Table 123. AstraZeneca Recent Developments
Table 124. NeoGenomics Laboratories Basic Information
Table 125. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 126. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 127. NeoGenomics Laboratories Business Overview
Table 128. NeoGenomics Laboratories Recent Developments
Table 129. AmoyDx Basic Information
Table 130. AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 131. AmoyDx Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 132. AmoyDx Business Overview
Table 133. AmoyDx Recent Developments
Table 134. Annoroad Basic Information
Table 135. Annoroad Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 136. Annoroad Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 137. Annoroad Business Overview
Table 138. Annoroad Recent Developments
Table 139. Burning Rock Biotech Basic Information
Table 140. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 141. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 142. Burning Rock Biotech Business Overview
Table 143. Burning Rock Biotech Recent Developments
Table 144. Global Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Region (2026-2033) & (K MT)
Table 145. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Region (2026-2033) & (M USD)
Table 146. North America Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Country (2026-2033) & (K MT)
Table 147. North America Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country (2026-2033) & (M USD)
Table 148. Europe Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Country (2026-2033) & (K MT)
Table 149. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country (2026-2033) & (M USD)
Table 150. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Region (2026-2033) & (K MT)
Table 151. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Region (2026-2033) & (M USD)
Table 152. South America Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Country (2026-2033) & (K MT)
Table 153. South America Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country (2026-2033) & (M USD)
Table 154. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Country (2026-2033) & (Units)
Table 155. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country (2026-2033) & (M USD)
Table 156. Global Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Type (2026-2033) & (K MT)
Table 157. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Type (2026-2033) & (M USD)
Table 158. Global Circulating Tumour DNA (ctDNA) Testing Price Forecast by Type (2026-2033) & (USD/MT)
Table 159. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) Forecast by Application (2026-2033)
Table 160. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Application (2026-2033) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Circulating Tumour DNA (ctDNA) Testing Market Size Comparison by Region (M USD)
Table 5. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Circulating Tumour DNA (ctDNA) Testing Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Circulating Tumour DNA (ctDNA) Testing Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumour DNA (ctDNA) Testing as of 2024)
Table 10. Global Market Circulating Tumour DNA (ctDNA) Testing Average Price (USD/MT) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Circulating Tumour DNA (ctDNA) Testing Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Circulating Tumour DNA (ctDNA) Testing Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Circulating Tumour DNA (ctDNA) Testing Sales by Type (K MT)
Table 26. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Type (M USD)
Table 27. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) by Type (2020-2025)
Table 28. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Type (2020-2025)
Table 29. Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) by Type (2020-2025)
Table 30. Global Circulating Tumour DNA (ctDNA) Testing Market Size Share by Type (2020-2025)
Table 31. Global Circulating Tumour DNA (ctDNA) Testing Price (USD/MT) by Type (2020-2025)
Table 32. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) by Application
Table 33. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Application
Table 34. Global Circulating Tumour DNA (ctDNA) Testing Sales by Application (2020-2025) & (K MT)
Table 35. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Application (2020-2025)
Table 36. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2020-2025) & (M USD)
Table 37. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Application (2020-2025)
Table 38. Global Circulating Tumour DNA (ctDNA) Testing Sales Growth Rate by Application (2020-2025)
Table 39. Global Circulating Tumour DNA (ctDNA) Testing Sales by Region (2020-2025) & (K MT)
Table 40. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region (2020-2025)
Table 41. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2020-2025) & (M USD)
Table 42. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2020-2025)
Table 43. North America Circulating Tumour DNA (ctDNA) Testing Sales by Country (2020-2025) & (K MT)
Table 44. North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Circulating Tumour DNA (ctDNA) Testing Sales by Country (2020-2025) & (K MT)
Table 46. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2020-2025) & (M USD)
Table 49. South America Circulating Tumour DNA (ctDNA) Testing Sales by Country (2020-2025) & (K MT)
Table 50. South America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2020-2025) & (M USD)
Table 53. Global Circulating Tumour DNA (ctDNA) Testing Production (K MT) by Region(2020-2025)
Table 54. Global Circulating Tumour DNA (ctDNA) Testing Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Region (2020-2025)
Table 56. Global Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 57. North America Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 58. Europe Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 59. Japan Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 60. China Circulating Tumour DNA (ctDNA) Testing Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 61. Nexomics Basic Information
Table 62. Nexomics Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 63. Nexomics Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 64. Nexomics Business Overview
Table 65. Nexomics SWOT Analysis
Table 66. Nexomics Recent Developments
Table 67. Roche Basic Information
Table 68. Roche Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 69. Roche Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 70. Roche Business Overview
Table 71. Roche SWOT Analysis
Table 72. Roche Recent Developments
Table 73. ORIOMICS Basic Information
Table 74. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 75. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 76. ORIOMICS Business Overview
Table 77. ORIOMICS SWOT Analysis
Table 78. ORIOMICS Recent Developments
Table 79. Signatera Basic Information
Table 80. Signatera Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 81. Signatera Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 82. Signatera Business Overview
Table 83. Signatera Recent Developments
Table 84. Illumina Basic Information
Table 85. Illumina Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 86. Illumina Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 87. Illumina Business Overview
Table 88. Illumina Recent Developments
Table 89. Sysmex Corporation Basic Information
Table 90. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 91. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 92. Sysmex Corporation Business Overview
Table 93. Sysmex Corporation Recent Developments
Table 94. Bio-Rad Basic Information
Table 95. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 96. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 97. Bio-Rad Business Overview
Table 98. Bio-Rad Recent Developments
Table 99. Biocartis Basic Information
Table 100. Biocartis Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 101. Biocartis Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 102. Biocartis Business Overview
Table 103. Biocartis Recent Developments
Table 104. QIAGEN Basic Information
Table 105. QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 106. QIAGEN Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 107. QIAGEN Business Overview
Table 108. QIAGEN Recent Developments
Table 109. GuardantHealth Basic Information
Table 110. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 111. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 112. GuardantHealth Business Overview
Table 113. GuardantHealth Recent Developments
Table 114. GSK plc Basic Information
Table 115. GSK plc Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 116. GSK plc Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 117. GSK plc Business Overview
Table 118. GSK plc Recent Developments
Table 119. AstraZeneca Basic Information
Table 120. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 121. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 122. AstraZeneca Business Overview
Table 123. AstraZeneca Recent Developments
Table 124. NeoGenomics Laboratories Basic Information
Table 125. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 126. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 127. NeoGenomics Laboratories Business Overview
Table 128. NeoGenomics Laboratories Recent Developments
Table 129. AmoyDx Basic Information
Table 130. AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 131. AmoyDx Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 132. AmoyDx Business Overview
Table 133. AmoyDx Recent Developments
Table 134. Annoroad Basic Information
Table 135. Annoroad Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 136. Annoroad Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 137. Annoroad Business Overview
Table 138. Annoroad Recent Developments
Table 139. Burning Rock Biotech Basic Information
Table 140. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Overview
Table 141. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 142. Burning Rock Biotech Business Overview
Table 143. Burning Rock Biotech Recent Developments
Table 144. Global Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Region (2026-2033) & (K MT)
Table 145. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Region (2026-2033) & (M USD)
Table 146. North America Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Country (2026-2033) & (K MT)
Table 147. North America Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country (2026-2033) & (M USD)
Table 148. Europe Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Country (2026-2033) & (K MT)
Table 149. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country (2026-2033) & (M USD)
Table 150. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Region (2026-2033) & (K MT)
Table 151. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Region (2026-2033) & (M USD)
Table 152. South America Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Country (2026-2033) & (K MT)
Table 153. South America Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country (2026-2033) & (M USD)
Table 154. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Country (2026-2033) & (Units)
Table 155. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Country (2026-2033) & (M USD)
Table 156. Global Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Type (2026-2033) & (K MT)
Table 157. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Type (2026-2033) & (M USD)
Table 158. Global Circulating Tumour DNA (ctDNA) Testing Price Forecast by Type (2026-2033) & (USD/MT)
Table 159. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) Forecast by Application (2026-2033)
Table 160. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Application (2026-2033) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Circulating Tumour DNA (ctDNA) Testing
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD), 2024-2033
Figure 5. Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) (2020-2033)
Figure 6. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Circulating Tumour DNA (ctDNA) Testing Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Circulating Tumour DNA (ctDNA) Testing Product Life Cycle
Figure 13. Circulating Tumour DNA (ctDNA) Testing Sales Share by Manufacturers in 2024
Figure 14. Global Circulating Tumour DNA (ctDNA) Testing Revenue Share by Manufacturers in 2024
Figure 15. Circulating Tumour DNA (ctDNA) Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Circulating Tumour DNA (ctDNA) Testing Average Price (USD/MT) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Circulating Tumour DNA (ctDNA) Testing Revenue in 2024
Figure 18. Industry Chain Map of Circulating Tumour DNA (ctDNA) Testing
Figure 19. Global Circulating Tumour DNA (ctDNA) Testing Market PEST Analysis
Figure 20. Global Circulating Tumour DNA (ctDNA) Testing Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Type
Figure 27. Sales Market Share of Circulating Tumour DNA (ctDNA) Testing by Type (2020-2025)
Figure 28. Sales Market Share of Circulating Tumour DNA (ctDNA) Testing by Type in 2024
Figure 29. Market Size Share of Circulating Tumour DNA (ctDNA) Testing by Type (2020-2025)
Figure 30. Market Size Share of Circulating Tumour DNA (ctDNA) Testing by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Application
Figure 33. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Application (2020-2025)
Figure 34. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Application in 2024
Figure 35. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Application (2020-2025)
Figure 36. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Application in 2024
Figure 37. Global Circulating Tumour DNA (ctDNA) Testing Sales Growth Rate by Application (2020-2025)
Figure 38. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region (2020-2025)
Figure 39. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2020-2025)
Figure 40. North America Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country in 2024
Figure 43. North America Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country in 2024
Figure 45. U.S. Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Circulating Tumour DNA (ctDNA) Testing Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Circulating Tumour DNA (ctDNA) Testing Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Circulating Tumour DNA (ctDNA) Testing Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country in 2024
Figure 53. Europe Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country in 2024
Figure 55. Germany Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region in 2024
Figure 67. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region in 2024
Figure 68. China Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (K MT)
Figure 79. South America Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country in 2024
Figure 80. South America Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (M USD)
Figure 81. South America Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country in 2024
Figure 82. Brazil Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Circulating Tumour DNA (ctDNA) Testing Production Market Share by Region (2020-2025)
Figure 103. North America Circulating Tumour DNA (ctDNA) Testing Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Circulating Tumour DNA (ctDNA) Testing Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Circulating Tumour DNA (ctDNA) Testing Production (K MT) Growth Rate (2020-2025)
Figure 106. China Circulating Tumour DNA (ctDNA) Testing Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Circulating Tumour DNA (ctDNA) Testing Market Share Forecast by Type (2026-2033)
Figure 111. Global Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Application (2026-2033)
Figure 112. Global Circulating Tumour DNA (ctDNA) Testing Market Share Forecast by Application (2026-2033)
Figure 1. Product Picture of Circulating Tumour DNA (ctDNA) Testing
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD), 2024-2033
Figure 5. Global Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) (2020-2033)
Figure 6. Global Circulating Tumour DNA (ctDNA) Testing Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Circulating Tumour DNA (ctDNA) Testing Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Circulating Tumour DNA (ctDNA) Testing Product Life Cycle
Figure 13. Circulating Tumour DNA (ctDNA) Testing Sales Share by Manufacturers in 2024
Figure 14. Global Circulating Tumour DNA (ctDNA) Testing Revenue Share by Manufacturers in 2024
Figure 15. Circulating Tumour DNA (ctDNA) Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Circulating Tumour DNA (ctDNA) Testing Average Price (USD/MT) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Circulating Tumour DNA (ctDNA) Testing Revenue in 2024
Figure 18. Industry Chain Map of Circulating Tumour DNA (ctDNA) Testing
Figure 19. Global Circulating Tumour DNA (ctDNA) Testing Market PEST Analysis
Figure 20. Global Circulating Tumour DNA (ctDNA) Testing Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Type
Figure 27. Sales Market Share of Circulating Tumour DNA (ctDNA) Testing by Type (2020-2025)
Figure 28. Sales Market Share of Circulating Tumour DNA (ctDNA) Testing by Type in 2024
Figure 29. Market Size Share of Circulating Tumour DNA (ctDNA) Testing by Type (2020-2025)
Figure 30. Market Size Share of Circulating Tumour DNA (ctDNA) Testing by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Application
Figure 33. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Application (2020-2025)
Figure 34. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Application in 2024
Figure 35. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Application (2020-2025)
Figure 36. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Application in 2024
Figure 37. Global Circulating Tumour DNA (ctDNA) Testing Sales Growth Rate by Application (2020-2025)
Figure 38. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region (2020-2025)
Figure 39. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2020-2025)
Figure 40. North America Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country in 2024
Figure 43. North America Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country in 2024
Figure 45. U.S. Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Circulating Tumour DNA (ctDNA) Testing Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Circulating Tumour DNA (ctDNA) Testing Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Circulating Tumour DNA (ctDNA) Testing Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Circulating Tumour DNA (ctDNA) Testing Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country in 2024
Figure 53. Europe Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country in 2024
Figure 55. Germany Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region in 2024
Figure 67. Asia Pacific Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region in 2024
Figure 68. China Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (K MT)
Figure 79. South America Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country in 2024
Figure 80. South America Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (M USD)
Figure 81. South America Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country in 2024
Figure 82. Brazil Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Circulating Tumour DNA (ctDNA) Testing Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Circulating Tumour DNA (ctDNA) Testing Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Circulating Tumour DNA (ctDNA) Testing Production Market Share by Region (2020-2025)
Figure 103. North America Circulating Tumour DNA (ctDNA) Testing Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Circulating Tumour DNA (ctDNA) Testing Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Circulating Tumour DNA (ctDNA) Testing Production (K MT) Growth Rate (2020-2025)
Figure 106. China Circulating Tumour DNA (ctDNA) Testing Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Circulating Tumour DNA (ctDNA) Testing Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Circulating Tumour DNA (ctDNA) Testing Market Share Forecast by Type (2026-2033)
Figure 111. Global Circulating Tumour DNA (ctDNA) Testing Sales Forecast by Application (2026-2033)
Figure 112. Global Circulating Tumour DNA (ctDNA) Testing Market Share Forecast by Application (2026-2033)
